There has been some recent press coverage stating those aged 16 and over who live with immunosuppressed adults should be prioritised for covid-19 vaccination alongside priority group 6 (people aged 16 to 65 who have a clinical condition that puts them at higher risk).
This would include people living in households with an adult who has a weakened immune system, such as those with blood cancer or HIV, or people on immunosuppressive treatment, including chemotherapy. A full list of the relevant conditions can be found further down this post.
We have already received several calls this morning regarding this. The Covid line is currently very busy booking patients for their second vaccinations, and we ask that if you live with someone who is immunosuppressed but have not yet been called for your first vaccination, rather than calling the Practice if at all possible please go to our website and submit your details via the Contact the Practice page: /…/contact-the…/
and we will get back to you.
Thank you for your co-operation
Full list of Immunocompromised Conditions
Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).
Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.
Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.
Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma and those with systemic lupus erythematosus and rheumatoid arthritis, and psoriasis who may require long term immunosuppressive treatments.